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BASIC RESEARCH STUDIES
The administration of low–molecular weight
heparin (LMWH) for the prevention of deep venous
thrombosis (DVT) is highly efficacious. However,
the main disadvantage of LMWH therapy is the sub-
cutaneous route of administration. From the
patient’s perspective, the subcutaneous administra-
tion of LMWH on a twice-a-day basis has been
noted to be quite painful.
As with other forms of heparin therapy, attempts
have been made with LMWH to administer the
medication through the gastrointestinal tract.
However, the gastrointestinal absorption of LMWH
alone has not been feasible or dependable. The rela-
tively large size and the negative charge of the
LMWH molecule do not allow the gastrointestinal
absorption of this medication. Thus, the oral admin-
istration of LMWH therapy has not been successful.
Emisphere Technologies (Tarrytown, NY) has
developed a carrier compound that will allow the
LMWH molecule to be administered orally. The car-
rier compound sodium N[10-(2-hydroxybenzoyl)
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amino]decanoate (SNAD) is a novel delivery agent
that facilitates the gastrointestinal absorption of
LMWH. SNAD is a carrier molecule that has been
specifically created for LMWH therapy. When mixed
together, SNAD and LMWH form a noncovalent
interaction that allows the passage of this complex
through the mucosa of the gastrointestinal tract and
into the bloodstream. Once in the bloodstream, the
SNAD molecule dissociates from the LMWH and
allows the unchanged LMWH molecule to effect
anticoagulation.
The primary hypothesis of this experiment was
that the oral administration of LMWH and its deliv-
ery agent SNAD would prevent the formation of
DVT in a rat model of venous thrombosis. Because
the systemic levels of LMWH can be inferred from
the plasma levels of anti-factor Xa, the secondary
hypothesis of this experiment was that the combina-
tion of oral LMWH and SNAD therapy would
increase the plasma levels of anti-factor Xa.
MATERIALS AND METHODS
Sixty Sprague-Dawley rats (weight, 250 to 300
g) were assigned to five experimental groups (n = 12
each). The group assignments were as follows:
group 1 (control), oral bolus of saline solution (2
mL); group 2, oral LMWH (15 mg/kg; Enoxiparin-
Rhone-Poulenc Rorer Pharmaceuticals, Collegeville,
Pa) via gavage tube; group 3, oral SNAD (300
mg/kg) via gavage tube; group 4, subcutaneous
[SQ] LMWH (5 mg/kg); and group 5, oral bolus of
LMWH (15 mg/kg) and SNAD (300 mg/kg) via
gavage. All the test medications were administered
30 minutes before the operative procedure. The ani-
mals were administered anesthesia with an intramus-
cular injection of ketamine hydrochloride (72
mg/kg) and acepromazine maleate (0.3 mg/kg).
The surgical procedure was developed by Blake
et al1 in 1959 and has been previously described.2
Briefly, through a midline cervical incision, the left
jugular vein was identified, dissected, and isolated
from its surrounding structures. The external jugu-
lar branch was ligated and divided. The remaining
jugular vein was approximately 1.0 to 1.5 cm in
length. The jugular vein then was occluded with
microscopic vascular clamps and bathed in a solution
of absolute ethanol and 10% formalin. After 2 min-
utes, the clamps were removed and the luminal flow
was reestablished. At this point, the skin was closed
and the animal was allowed to recover. Two hours
after bathing the jugular vein in the sclerosant mix-
ture, the animal was reanesthetized. The incision
then was reopened, and the jugular vein was once
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again isolated with microscopic vascular clamps.
With an operating microscope, the jugular vein was
externally examined for the presence of intraluminal
thrombus. The jugular vein then was excised. The
thrombus was meticulously extracted from the vein
and weighed. The veins that had no thrombus were
counted as zero in the calculation of the average
thrombus weight.
A separate experiment was undertaken to specif-
ically measure the plasma levels of anti-factor Xa. A
group of 30 Sprague-Dawley rats that weighed 250
to 300 g each were divided into four groups. Group
A (n = 10) was administered a subcutaneous injec-
tion of LMWH (5 mg/kg). Group B (n = 10) was
administered a bolus of LMWH via gavage (15
mg/kg) in combination with the carrier molecule
SNAD (300 mg/kg). Group C (n = 5) was admin-
istered gavage LMWH (15 mg/kg) alone. Group D
(n = 5) was administered a gavage bolus of the car-
rier compound SNAD (300 mg/kg). Blood samples
were obtained from these animals at 0 and 30 min-
utes and at 1, 2, 3, and 4 hours after the administra-
tion of the test substance. The blood samples were
collected in vials that contained sodium citrate and
were placed in a centrifuge at 3000 rpm for 10 min-
utes to separate the cellular components from the
plasma. The separated plasma then was placed in a
colorimetric quantitative assay to test for the pres-
ence of anti-factor Xa (Chromogenix, MoIndal,
Sweden).
The statistical analyses that were applied to this
experiment were the c 2 test and analysis of variance.
The Institutional Animal Care and Use Committee
of the Alton Ochsner Medical Foundation granted
approval for this experiment.
RESULTS
The first portion of this experiment was noted to
have a mortality rate of 12.1% (seven of 58 rats).
The deaths were related to respiratory failure imme-
diately after the injection of the anesthetic. The ani-
mals that died before completion of the experimen-
tal protocol were excluded from the data and statis-
tical analyses. The final numbers of animals in each
group were as follows: group 1, n = 12; group 2, n
= 10; group 3, n = 9; group 4, n = 12; and group 5,
n = 10. There were no deaths in the second portion
of this experiment.
In situ assessment of thrombus. The visual
inspection of the rat jugular vein revealed the fol-
lowing results regarding the presence of intraluminal
thrombus: group 1 (control), 12 of 12 (100%) were
noted to have intraluminal thrombus; group 2 (oral
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LMWH), eight of 10 (80%) had intraluminal throm-
bus; group 3 (oral SNAD), nine of nine (100%) had
intraluminal thrombus; group 4 (SQ LMWH), one
of 12 (8.3%) had evidence of thrombus; and group
5 (LMWH/SNAD oral), none of 10 (0%) had intra-
luminal thrombus. When these values were com-
pared statistically, it was noted that the LMWH SQ
group and the oral LMWH/SNAD groups had sig-
nificantly less evidence of intravascular thrombosis
than did the other three groups (P < .05). In addi-
tion, when the LMWH SQ group was compared
with the oral LMWH/SNAD group, there was no
statistically significant difference in the presence of
luminal thrombus (Fig 1).
Quantitative assessment of thrombus. After
the inspection of the jugular vein for the presence of
thrombus and vessel patency, the vein was excised
and the thrombus was extracted. The average
thrombus weights were as follows (Fig 2): group l
(control), 7.5 ± 1.51 mg; group 2 (oral LMWH),
6.40 ± 1.34 mg; group 3 (oral SNAD), 8.22 ± 1.31
mg; group 4 (LMWH SQ), 0.75 ± 0.41 mg; and
group 5 (oral LMWH/SNAD), 0.42 ± 0.22 mg.
Statistical comparison results revealed that there was
a significant decrease in the thrombus weight in
those animals that were administered either LMWH
SQ or oral LMWH/SNAD as compared with the
other three groups of animals (P < .05). There was
no statistically significant difference in the average
thrombus weights of the LMWH SQ and oral
LMWH/SNAD groups when compared with each
other.
Quantitative measurement of anti-factor Xa.
The quantitative measurement of anti-factor Xa was
performed on a separate group of 30 animals that
were administered either LMWH SQ, oral LMWH/
SNAD, oral LMWH alone, or oral SNAD alone.
Blood was drawn at six time points throughout a 
4-hour time period (Fig 3). The animals that were
administered SQ LMWH were noted to exhibit
Fig 1. Jugular vein was examined for presence of thrombus while in situ. Animals in groups
4 and 5 displayed statistically significant decreased amount of visible thrombus (*P < .05, with
analysis of variance) as compared with groups 1, 2, and 3. No visible difference was noted
between groups 4 and 5 (#P = NS).
LMWH, Low–molecular weight heparin; SNAD, sodium N-[10-(2-hydroxybenzoyl)amino]
decanoate; SQ, subcutaneous.
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serum levels of anti-factor Xa that rose above base-
line and remained elevated for the 4-hour course of
the study. The levels of anti-factor Xa in the animals
that were administered the oral combination of
LMWH and SNAD were also elevated above base-
line and remained elevated for the 4-hour time peri-
od. The animals that were administered oral LMWH
alone also had a significant elevation of anti-factor
Xa activity above baseline. The animals that were
administered oral SNAD revealed no increase in
anti-factor Xa activity. At each time point through-
out the 4-hour experimental period, statistical com-
parison results revealed that those animals that were
administered either LMWH SQ, oral LMWH/
SNAD, or oral LMWH alone exhibited measured
activities of anti-factor Xa that were significantly ele-
vated as compared with the respective baseline levels
(P < .05). Comparison results among these three
groups revealed that the plasma levels of anti-factor
Xa are highest in those animals that were adminis-
tered the subcutaneous injection of LMWH (5
mg/kg). At all timepoints, the animals that were
administered the oral combination of LMWH (15
mg/kg) and SNAD were noted to have statistically
significant elevated levels of anti-factor Xa activity as
compared with LMWH alone. However, at the third
hour, the levels of anti-factor Xa were increased but
did not reach statistical significance (P = .07).
DISCUSSION
In this study, the oral administration of LMWH
and its carrier compound SNAD prevented the for-
mation of intraluminal thrombi in the rat model of
DVT. Both the subjective and the objective criteria
were found to be effected by the administration of
LMWH with its carrier compound. When compared
with the control group, the animals that were admin-
istered the oral combination of LMWH and SNAD
had decreased visible thrombi. Quantitatively, the
thrombus weight of these animals was significantly
Fig 2. Thrombus was extracted from excised jugular vein. Animals in groups 4 and 5 dis-
played quantitatively less thrombus (*P < .05, with analysis of variance) compared with groups
1, 2, and 3. No significant difference in weight of extracted thrombus was noted between
groups 4 and 5 (#P = NS).
LMWH, Low–molecular weight heparin; SNAD, sodium N-[10-(2-hydroxybenzoyl)amino]
decanoate; SQ, subcutaneous.
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less than that of the control group. Oral administra-
tion of LMWH/SNAD was as effective as subcuta-
neous LMWH in the prevention of jugular venous
thrombosis.
In contrast to unfractionated heparin therapy, the
smaller LMWH has little effect on inhibiting factor II
but has a similar inhibitory effect on factor X. The abil-
ity of LMWH to bind anti-thrombin III and subse-
quently inhibit factor Xa is the cornerstone of the anti-
coagulant properties.3 With the measurement of the
serum levels of anti-factor Xa, we were able to infer the
effect of LMWH and to test the anticoagulant proper-
ties of this novel oral combination. The animals that
were administered either oral LMWH/SNAD or SQ
LMWH had statistically greater levels of anti-factor Xa
than did the others. The animals that were adminis-
tered subcutaneous LMWH were noted to have even
higher serum levels of anti-factor Xa. This suggested
that perhaps an even higher dose of oral medication
was needed to reach equivalent levels of anti-factor Xa.
Yet, higher levels may not be necessary because the
present dosages of oral LMWH/SNAD were effective
in the prevention of DVT in this model of DVT. The
fact that oral LMWH at 15 mg/kg exhibited an
increase of anti-factor Xa levels suggested some gas-
trointestinal absorption of this substance without the
carrier agent. This has been noted previously with
unfractionated heparin therapy only. That the same
dosage of LMWH combined with the carrier SNAD
was associated with much higher levels of anti-factor
Xa suggested significantly enhanced absorption of
LMWH with the addition of oral SNAD.
What can be noted from this study is that the
addition of SNAD to LMWH allows for the gas-
Fig 3. Anti-factor Xa levels were measured and depicted in IU/mL. All three preparations of
low–molecular weight heparin (LMWH) caused statistically significant increases in levels of anti-
factor Xa above baseline (*P < .05). Oral administration of LMWH with its carrier sodium N-
[10-(2-hydroxybenzoyl)amino]decanoate (SNAD) caused statistically significant elevation in
anti-factor Xa levels (#P < .05) when compared with LMWH alone. Subcutaneous (SQ) admin-
istration of LMWH at one third of oral dose causes dramatic elevation of anti-factor Xa levels.
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trointestinal absorption of the LMWH molecule.
This is clearly evident in the second part of the exper-
iment where oral LMWH therapy alone gives rise to
a small, yet statistically significant, increase in anti-
factor Xa levels as compared with baseline. However,
when LMWH and SNAD are combined in an oral
preparation, the anti-factor Xa activity reached levels
that are considered to be therapeutic. In situ, the
combination of LMWH/SNAD prevented venous
thrombosis in this animal model, whereas oral
LMWH therapy alone had no measurable effect on
the prevention of venous thrombosis. Given the fact
that LMWH/SNAD reached therapeutic levels of
anti-factor Xa, there may be an overdose of the
LMWH because of its enhanced bioavailability when
combined with SNAD. This is a potential flaw of this
study. There may a be a lower dose of LMWH that
can be combined with SNAD to achieve lower yet
preventative levels of anti-factor Xa, rather than lev-
els that appear to be therapeutic. Although we have
shown that SNAD functions well in its capacity as a
carrier of LMWH, the possibility exists that SNAD
enhanced the bioavailability of LMWH and has
allowed this compound to function as a therapeutic
method as opposed to a preventative one.
Further experimentation with this model of venous
thrombosis may not be worthwhile because we have
already shown that SNAD works appropriately as a
delivery agent for LMWH. More relevant animal
models must be sought that mimic the size and char-
acter of human veins and DVT such that we may fur-
ther explore the subtleties of the LMWH/SNAD
combination.
In summary, LMWH administered orally in
combination with the carrier SNAD resulted in the
prevention of venous thrombosis in a rat model of
venous thrombosis. Elevated serum levels of anti-
factor Xa were noted in the study groups, which
confirmed the systemic absorption of LMWH
through the gastrointestinal tract. These results are
relevant yet are not ready for extrapolation to the
prevention of venous thrombosis in humans because
the nuances of dosage, side effects, and cost still
need to be investigated. The clinical usefulness of
this oral combination can be imagined, but it clearly
depends on the results of more intense investigations
of this novel method of administration of LMWH.
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Dr John F. Eidt (Little Rock, Ark). This is the first
step on the road to the ideal anticoagulant—that is, an oral
anticoagulant that takes daily dosing, does not necessitate
monitoring, has a low bleeding risk, and is cheap. I think
you can see from the results today that we are not quite
there, but I think it is a good first step.
Heparin is composed of glucosamine and either L-
iduronic acid or D-glucuronic acid in chains of variable
length, with a molecular weight up to 30,000 Daltons. The
anticoagulant effect of heparin is mediated primarily
through acceleration of the natural anticoagulant anti-
thrombin III, which basically inhibits factor IIa, or throm-
bin, and, to a lesser extent, factor Xa. The efficacy of
low–molecular weight heparin resides primarily in its abili-
ty to inhibit factor Xa with less inhibition of thrombin. It is
thought that inhibition of factor Xa, without significantly
affecting thrombin, also accounts for the high efficacy and
low bleeding risk with low molecular weight heparin.
In the current study, the authors have used an oral
anticoagulant consisting of low–molecular weight heparin,
or enoxaparin, combined with a novel carrier, SNAD, to
reduce venous thrombosis in a rat model. In addition, the
authors have demonstrated dose-dependent inhibition of
factor Xa. The authors have speculated that this oral form
of low–molecular weight heparin may have significant
value in the management of venous thrombosis in humans
by eliminating its most important drawbacks, that is, the
cost and inconvenience of subcutaneous administration.
DISCUSSION
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I have four areas of questions. The first question deals
with the animal model itself. I would like the authors to
justify the use of this particular animal model of venous
thrombosis. In general, it is thought that two of three
components of Virchow’s triad are needed to be per-
turbed to induce thrombosis. In this model, stasis is 
clearly achieved with the ligation of the external jugular
vein, but the thrombotic stimulus in this model is rather 
a unphysiologic and caustic bathing of the vessel with
externally applied ethanol and formalin solution. So, my
question is, does this have anything to do with venous
thrombosis in humans?
My second question relates to dosing. One of the
obvious major drawbacks to the oral administration of a
drug is the unpredictability of absorption and bioavailabil-
ity, which could result in either underdosing or overdos-
ing. The authors have shown that the oral administration
of low–molecular weight heparin and SNAD was effective
in virtually every animal in reducing the presence of
thrombus in the treated group. My question relates to the
possibility of overdosage to achieve this uniform result.
The subcutaneous dose of low–molecular weight
heparin in this experiment, which was 5mg/kg, is five
times higher than the current recommendation for thera-
peutic anticoagulation with enoxaparin. So, although
bleeding complications with low–molecular weight heparin
are reported to be fewer than with unfractionated heparin,
it is still clearly possible to overdose low–molecular weight
heparin and bleeding risk does exist.
My second question is, were these animals overdosed
and were there signs of any bleeding, and could you have
achieved the same result with a lower dose?
It is generally believed that oral heparin without a car-
rier is ineffective because of acid neutralization in the
stomach and incomplete absorption because of the size
and charge of the molecule. It has been shown, though, by
Canadian researchers that large doses of heparin, like
400,000 units of oral heparin without a carrier, can be
given orally to prevent venous thrombosis in a model sim-
ilar to yours.
It appears that the reason such large doses have to be
given is that the heparin is taken up by the endothelium,
which leaves very little active heparin in the circulation.
I was interested in your last slide of the anti-factor Xa
levels where the oral low–molecular weight heparin was
given without a carrier and there was a steady increase in
the anti-factor Xa levels over time. Is that because of
low–molecular weight heparin that has been taken up by
endothelium and then slowly released into the circulation,
or do you have any idea of what happens to that low–mol-
ecular weight heparin?
And, lastly, I wanted to ask you a question about tox-
icity. Previous attempts to develop a carrier compound to
deliver heparin orally have been plagued by gastrointesti-
nal side effects in human volunteers—in particular, emesis.
Does the carrier used in this model have any significant
gastrointestinal toxicity, and did you look at any way at the
gastric mucosa of these rats to identify any evidence of gas-
tric injury?
I enjoyed the presentation. Thank you.
Dr Khashayar Salartash. Dr Eidt, I appreciate your
comments. They are very insightful. I will try to make the
responses fairly brief.
We chose the animal model because it is an easily
reproducible model of venous thrombosis, it is cheap, and,
at least in our three control groups, we had thrombosis in
all three groups. So, we believed that the animal model
itself was very good.
As far as dosing goes, the rat is very insensitive to
low–molecular weight heparin. That is why we had to use
such high doses. Before we embarked on this study, a
number of dosing trials were completed that basically
allowed us to recognize the appropriate dose of low–mol-
ecular weight heparin that would achieve the anti-factor
Xa level that we required for this experiment.
Regarding your question about bleeding, there were
no bleeding complications that we noted in our rats. We
did have about a 12.1% mortality rate, and that was really
related to the fact that a couple of the rats just died soon
after anesthesia.
As far as toxicity, I do not have any data on the toxicity
of SNAD. However, SNAC, (Sodium 8-[2(hydrobenzoyl)
Amino] Caprylate), which is very closely related to SNAD,
is a carrier that has been developed for the unfractionated
heparin and is associated at very high doses—that is about
five times the doses that are normally necessary, with nausea
and vomiting. But, again, I do not have any data on SNAD.
The level of anti-factor Xa that we saw for oral
low–molecular weight heparin alone was not a level that
achieves anticoagulation. The level of anti-Factor Xa that
is therapeutic is anywhere from 0.4 and above. In fact, an
anti-factor Xa level of 0.4 is equal to one to one and half
times normal Partial Thromboplastin Time (PTT). So, I
guess that answers your other question.
